• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cerevel Therapeutics Hldg Inc (NQ: CERE )

    42.71 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 42.71
    Bid (Size) 17.18 (1)
    Ask (Size) 44.99 (2)
    Prev. Close 42.71
    Today's Range 42.71 - 42.71
    52wk Range 19.59 - 43.59
    Shares Outstanding 8,830,700
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
    Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed. 
    Via Benzinga
    Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
    The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
    Via Investor's Business Daily

    Performance

    YTD
    +1.18%
    +1.18%
    1 Month
    +0.92%
    +0.92%
    3 Month
    +1.47%
    +1.47%
    6 Month
    +80.59%
    +80.59%
    1 Year
    +36.45%
    +36.45%

    More News

    Read More
    Tuesday Talk: Big-Tech Under Attack
    Via Talk Markets
    Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
    Via Benzinga
    3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
    Via InvestorPlace
    Is AbbVie Stock a Buy Now?
    Via The Motley Fool
    This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
    Via Benzinga
    UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
    Via Benzinga
    AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
    Via Benzinga
    AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    ABBV: This Top Biotech Just Went On A Buying Spree
    Via Talk Markets
    7 Dividend Aristocrats That Will Pay You for Years to Come
    Via InvestorPlace
    CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
    Via Benzinga
    Is AbbVie Stock a Buy Now?
    Via The Motley Fool
    Topics Intellectual Property
    Exposures Intellectual Property
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    Via Benzinga
    JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    The 7 Most Undervalued Growth Stocks to Buy in December
    Via InvestorPlace
    AbbVie continues shopping spree with biotech buyout
    Via MarketBeat
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.